Skip to main content

Transforming the understanding
and treatment of mental illnesses.

Science News About Treatments

Word cloud with text arranged on background.
NIH, FDA and 15 Private Organizations Join Forces to Increase Effective Gene Therapies for Rare Diseases

The newly launched Bespoke Gene Therapy Consortium (BGTC), part of the NIH Accelerating Medicines Partnership (AMP) program, aims to optimize and streamline the gene therapy development process to help fill the unmet medical needs of people with rare diseases.

 A high-powered black and white microscope image showing exosomes, nanosized parts of cells. (Credit: Surya Shrivastava / City of Hope
Researchers Use Exosome-Based Strategy to Block HIV in Mice

In this NIMH-funded study, researchers used exosomes to deliver novel protein into the cells of mice infected with HIV. The protein attached to HIV’s genetic material and prevented it from replicating, resulting in reduced levels of HIV in the bone marrow, spleen, and brain.

Dr. Carlos Zarate
NIMH’s Carlos Zarate Jr., M.D., Elected to National Academy of Medicine

Carlos Zarate Jr., M.D., chief of the Experimental Therapeutics and Pathophysiology Branch within the NIMH Intramural Research Program, has been elected to the National Academy of Medicine.

illustration of a human head with braiwaves superimposed at the top
Neural Signature Identifies People Likely to Respond to Antidepressant Medication

NIH-funded research uses machine learning algorithm to predict individual response to a commonly-prescribed antidepressant.

doctor standing by IV pole
Side Effects Mild, Brief with Single Antidepressant Dose of Intravenous Ketamine

A single, low-dose ketamine infusion was relatively free of side effects for patients with treatment-resistant depression.

a group of young people sits on grass in the sun
NIH Announces Funding Awards for National Early Psychosis Learning Community

NIMH awarded six research grants for studies to develop a learning health care system for the treatment of early psychosis.

mom holding baby with pacifier
Bench-to-Bedside: NIMH Research Leading to Brexanolone, First-Ever Drug Specifically for Postpartum Depression

FDA approval of the postpartum depression treatment brexanolone represents the final phase of a bench-to-bedside journey for this drug — a journey that began in the NIMH Intramural Research Program. NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, this new drug.